Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Sab Biotherapeutics Inc (NQ: SABS )

0.4100 -0.0084 (-2.01%)
Streaming Delayed Price Updated: 11:04 AM EDT, Mar 30, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 25,896
Open 0.4270
Bid (Size) 0.4067 (2)
Ask (Size) 0.4186 (1)
Prev. Close 0.4184
Today's Range 0.4001 - 0.4270
52wk Range 0.4004 - 4.400
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Stocks That Hit 52-Week Lows On Wednesday
  On Wednesday, 81 companies hit new 52-week lows. 
Via Benzinga
Stocks That Hit 52-Week Lows On Monday
  On Monday, 89 stocks made new 52-week lows. 
Via Benzinga

Performance

YTD
-36.92%
-36.92%
1 Month
-40.58%
-40.58%
3 Month
-24.49%
-24.49%
6 Month
-42.01%
-42.01%
1 Year
-81.78%
-81.78%

More News

Read More
SAB Biotherapeutics CEO Eddie Sullivan, PhD, to Present Next Generation Biologics in Immunology at BIO CEO & Investor Conference
From SAB Biotherapeutics, Inc.
Via Globe NewsWire
Stocks That Hit 52-Week Lows On Friday
Via Benzinga
SAB Biotherapeutics Receives an Additional $8.2 Million in Closeout of DoD Contract
From SAB Biotherapeutics, Inc.
Via Globe NewsWire
EXCLUSIVE: SAB Biotherapeutics Receives Additional $8.2M In Closeout Of COVID-19 DoD Contract
Via Benzinga
12 Health Care Stocks Moving In Wednesday's After-Market Session
Via Benzinga
SAB Biotherapeutics Successfully Concludes IND-Enabling GLP Toxicology Study for SAB-142, a Novel Immunotherapeutic for Type 1 Diabetes
From SAB Biotherapeutics, Inc.
Via Globe NewsWire
EXCLUSIVE: SAB Biotherapeutics' Type 1 Diabetes Candidate Moves One Step Closer To Enter Human Trials With Completion Of Toxicology Study
Via Benzinga
SAB Biotherapeutics’ CMO Alexandra Kropotova to Deliver Presentation on Next Generation Biologics in Immunology at Biotech Showcase
From SAB Biotherapeutics, Inc.
Via Globe NewsWire
SAB Biotherapeutics Novel DiversitAb™ Platform Proven to Develop Anti-idiotype Antibodies to Help Treat Autoimmune Diseases
From SAB Biotherapeutics, Inc.
Via Globe NewsWire
Stocks That Hit 52-Week Lows On Thursday
Via Benzinga
SAB Biotherapeutics CMO Selected to Present at the January 2023 Biotech Showcase in San Francisco
From SAB Biotherapeutics, Inc.
Via Globe NewsWire
SAB Biotherapeutics Announces $7.9 Million Private Placement of Common Stock
From SAB Biotherapeutics, Inc.
Via Globe NewsWire
Benzinga's Top Ratings Upgrades, Downgrades For November 29, 2022
Via Benzinga
SAB Biotherapeutics Initiates IND-Enabling GLP Toxicology Study for SAB-142, Novel Immunotherapeutic for Type 1 Diabetes
From SAB Biotherapeutics, Inc.
Via Globe NewsWire
SAB Biotherapeutics Provides Company Update for Q3 2022 Financial Results
From SAB Biotherapeutics, Inc.
Via Globe NewsWire
EXCLUSIVE: SAB Biotherapeutics Posts Wider Quarterly Loss, Cash Runway Expected Into Mid-2023
Via Benzinga
SAB Biotherapeutics Presents ‘Novel Biologic Therapeutics for Infectious Diseases’ at U.S. Pharma Partnering Summit 2022
From SAB Biotherapeutics, Inc.
Via Globe NewsWire
SAB Biotherapeutics Presents Overview of DiversitAb™ Platform and Data Showing Benefits of Fully-Human Polyclonal Antibodies Derived from Cows vs. Human-Derived Plasma, at 2022 Plasma Product Biotechnology Conference
From SAB Biotherapeutics, Inc.
Via Globe NewsWire
EXCLUSIVE: SAB Biotherapeutics Says Influenza, COVID-19 Candidates Showing Broad Efficacy Against Variants
Via Benzinga
12 Health Care Stocks Moving In Tuesday's Intraday Session
Via Benzinga
SAB Biotherapeutics Announces Exclusive Manufacturing Partnership with Emergent BioSolutions
From SAB Biotherapeutics, Inc.
Via Globe NewsWire
12 Health Care Stocks Moving In Monday's Intraday Session
Via Benzinga
Why NVIDIA, Microsoft And Amazon Shares Traded Lower; Here Are 73 Biggest Movers From Friday
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.